Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
177 hedge funds and large institutions have $615M invested in Meridian Bioscience Inc in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 69 increasing their positions, 49 reducing their positions, and 22 closing their positions.
657% more call options, than puts
Call options by funds: $2.13M | Put options by funds: $281K
41% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 49
14% more capital invested
Capital invested by funds: $541M → $615M (+$73.9M)
5% less funds holding
Funds holding: 186 → 177 (-9)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.74M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.05M |
| 3 |
Renaissance Technologies
New York
|
+$3.29M |
| 4 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$3.16M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.9M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$5.14M |
| 3 |
Rafferty Asset Management
New York
|
-$4.43M |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$3.25M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$2.14M |
VIVO Hedge Fund Activity: Q2 2018 in Review
177 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q2 2018, worth a combined $615M — up 14% from $541M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of VIVO and 16 opened new positions — a net loss of 6 holders — while 49 trimmed existing stakes and 69 added.
The largest buyer was BlackRock, adding an estimated $7.74M. The largest seller was Millennium Management, cutting an estimated $5.9M.
- 177 institutional investors held Meridian Bioscience Inc (VIVO) as of Q2 2018, down from 186 in Q1 2018.
- Funds reported $615M of Meridian Bioscience Inc stock for Q2 2018, up 14% quarter-over-quarter.
- 16 funds opened new Meridian Bioscience Inc positions in Q2 2018 and 22 closed out, a net change of -6 holders.
- The largest Meridian Bioscience Inc buyer in Q2 2018 was BlackRock, an estimated $7.74M added.
- The largest Meridian Bioscience Inc seller in Q2 2018 was Millennium Management, an estimated $5.9M sold.
Based on aggregated 13F filings for Q2 2018.